

Sekundärprävention des ischämischen Hirnschlags

La prévention secondaire de l'accident vasculaire cérébral

Literatur / Références

1. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. *Lancet* 1991, 338(8779):1345–1349.
2. CAST: randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. CAST (Chinese Acute Stroke Trial) Collaborative Group. *Lancet* 1997, 349(9066):1641–1649.
3. The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. *Lancet* 1997, 349(9065):1569–1581.
4. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC: Antiplatelet therapy for acute ischaemic stroke. The Cochrane database of systematic reviews 2008(3):CD000029.
5. Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. *Journal of neurology, neurosurgery, and psychiatry* 1996, 60(2):197–199.
6. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. *The New England journal of medicine* 1991, 325(18):1261–1266.
7. Farrell B, Godwin J, Richards S, Warlow C: The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. *Journal of neurology, neurosurgery, and psychiatry* 1991, 54(12):1044–1054.
8. Campbell CL, Smyth S, Montalescot G, Steinhubl SR: Aspirin dose for the prevention of cardiovascular disease: a systematic review. *JAMA: the journal of the American Medical Association* 2007, 297(18):2018–2024.
9. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, Schwartz NE, Sonnenberg FA, Schulman S, Vandvik PO, Spencer FA et al: Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012, 141(2 Suppl):e601S-636S.
10. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW et al: Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. *The New England journal of medicine* 2005, 352(3):238–244.
11. Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J: Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. *Archives of neurology* 2005, 62(8):1217–1220.
12. Burger W, Chemnitz JM, Kneissl GD, Rucker G: Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation – review and meta-analysis. *Journal of internal medicine* 2005, 257(5):399–414.
13. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. *Lancet* 1996, 348(9038):1329–1339.
14. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. *Journal of the neurological sciences* 1996, 143(1–2):1–13.
15. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A: Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. *Lancet* 2006, 367(9523):1665–1673.
16. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P et al: Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *The New England journal of medicine* 2008, 359(12):1238–1251.
17. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. *Lancet* 2004, 364(9431):331–337.
18. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. *The New England journal of medicine* 2006, 354(16):1706–1717.
19. Lakhan SE, Sapko MT: Blood pressure lowering treatment for preventing stroke recurrence: a systematic review and meta-analysis. *International archives of medicine* 2009, 2(1):30.
20. Thompson AM, Hu T, Eshelbrenner CL, Reynolds K, He J, Bazzano LA: Antihypertensive treatment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. *JAMA: the journal of the American Medical Association* 2011, 305(9):913–922.
21. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB: Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease. *Stroke; a journal of cerebral circulation* 2008, 39(2):497–502.

22. Collins R, Armitage J, Parish S, Sleight P, Peto R: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. *Lancet* 2004, 363(9411):757–767.
23. Amarenco P, Bogousslavsky J, Callahan A, 3rd, Goldstein LB, Hennerici M, Rudolph AE, Silleesen H, Simunovic L, Szarek M, Welch KM et al: High-dose atorvastatin after stroke or transient ischemic attack. *The New England journal of medicine* 2006, 355(6):549–559.
24. Putaala J, Haapaniemi E, Kaste M, Tatlisumak T: Statins after ischemic stroke of undetermined etiology in young adults. *Neurology* 2011, 77(5):426–430.
25. Blanco M, Nombela F, Castellanos M, Rodriguez-Yanez M, Garcia-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA et al: Statin treatment withdrawal in ischemic stroke: a controlled randomized study. *Neurology* 2007, 69(9):904–910.
26. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. *The New England journal of medicine* 1991, 325(7):445–453.
27. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). *Lancet* 1998, 351(9113):1379–1387.
28. Bonati LH, Lyrer P, Ederle J, Featherstone R, Brown MM: Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. *The Cochrane database of systematic reviews* 2012, 9:CD000515.
29. Brott TG, Hobson RW, 2nd, Howard G, Roubin GS, Clark WM, Brooks W, Mackey A, Hill MD, Leimgruber PP, Sheffet AJ et al: Stenting versus endarterectomy for treatment of carotid-artery stenosis. *The New England journal of medicine* 2010, 363(1):11–23.
30. Bonati LH, Dobson J, Algra A, Branchereau A, Chatellier G, Fraedrich G, Mali WP, Zeumer H, Brown MM, Mas JL et al: Short-term outcome after stenting versus endarterectomy for symptomatic carotid stenosis: a preplanned meta-analysis of individual patient data. *Lancet* 2010, 376(9746):1062–1073.
31. Eckstein HH, Ringleb P, Allenberg JR, Berger J, Fraedrich G, Hacke W, Hennerici M, Stingele R, Fiehler J, Zeumer H et al: Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. *Lancet neurology* 2008, 7(10):893–902.
32. Lal BK, Beach KW, Roubin GS, Lutsep HL, Moore WS, Malas MB, Chiu D, Gonzales NR, Burke JL, Rinaldi M et al: Restenosis after carotid artery stenting and endarterectomy: a secondary analysis of CREST, a randomised controlled trial. *Lancet neurology* 2012, 11(9):755–763.
33. Mas JL, Trinquart L, Leys D, Albuquer JF, Rousseau H, Viguier A, Bossavy JP, Denis B, Piquet P, Garnier P et al: Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial. *Lancet neurology* 2008, 7(10):885–892.
34. Arquizan C, Trinquart L, Touboul PJ, Long A, Feasson S, Terriat B, Gobin-Metteil MP, Guidolin B, Cohen S, Mas JL: Restenosis is more frequent after carotid stenting than after endarterectomy: the EVA-3S study. *Stroke; a journal of cerebral circulation* 2011, 42(4):1015–1020.
35. Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, Janis LS, Lutsep HL, Barnwell SL, Waters MF et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. *The New England journal of medicine* 2011, 365(11):993–1003.
36. Meissner I, Khandheria BK, Heit JA, Petty GW, Sheps SG, Schwartz GL, Whisnant JP, Wiebers DO, Covalt JL, Petterson TM et al: Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based study. *Journal of the American College of Cardiology* 2006, 47(2):440–445.
37. Overell JR, Bone I, Lees KR: Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. *Neurology* 2000, 55(8):1172–1179.
38. Alsheikh-Ali AA, Thaler DE, Kent DM: Patent foramen ovale in cryptogenic stroke: incidental or pathogenic? *Stroke; a journal of cerebral circulation* 2009, 40(7):2349–2355.
39. Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, Di Angelantonio E, Di Tullio MR, Lutz JS, Elkind MS et al: An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. *Neurology* 2013, 81(7):619–625.
40. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP: Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. *Circulation* 2002, 105(22):2625–2631.
41. Orgera MA, O'Malley PG, Taylor AJ: Secondary prevention of cerebral ischemia in patent foramen ovale: systematic review and meta-analysis. *Southern medical journal* 2001, 94(7):699–703.
42. Agarwal S, Bajaj NS, Kumbhani DJ, Tuzcu EM, Kapadia SR: Meta-analysis of transcatheter closure versus medical therapy for patent foramen ovale in prevention of recurrent neurological events after presumed paradoxical embolism. *JACC Cardiovascular interventions* 2012, 5(7):777–789.
43. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM: Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. *Stroke; a journal of cerebral circulation* 2012, 43(2):422–431.
44. Flint AC, Banki NM, Ren X, Rao VA, Go AS: Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry. *Stroke; a journal of cerebral circulation* 2012, 43(10):2788–2790.
45. Miller DJ, Khan MA, Schultz LR, Simpson JR, Katramados AM, Russman AN, Mitsias PD: Outpatient cardiac telemetry detects a high rate of atrial fibrillation in cryptogenic stroke. *Journal of the neurological sciences* 2013, 324(1–2):57–61.
46. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M et al: Closure or medical therapy for cryptogenic stroke with patent foramen ovale. *The New England journal of medicine* 2012, 366(11):991–999.
47. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL: Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. *The New England journal of medicine* 2013, 368(12):1092–1100.
48. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS et al: Percutaneous closure of patent foramen ovale in cryptogenic embolism. *The New England journal of medicine* 2013, 368(12):1083–1091.

49. Mono ML, Geister L, Galimanis A, Jung S, Praz F, Arnold M, Fischer U, Wolff S, Findling O, Windecker S et al: Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events. *Stroke; a journal of cerebral circulation* 2011, 42(10):2891–2895.
50. Towfighi A, Ovbiagele B: The impact of body mass index on mortality after stroke. *Stroke; a journal of cerebral circulation* 2009, 40(8):2704–2708.
51. Vemmos K, Ntaios G, Spengos K, Savvari P, Vemmou A, Pappa T, Manios E, Georgiopoulos G, Alevizaki M: Association between obesity and mortality after acute first-ever stroke: the obesity-stroke paradox. *Stroke; a journal of cerebral circulation* 2011, 42(1):30–36.
52. Olsen TS, Dehlendorff C, Petersen HG, Andersen KK: Body mass index and poststroke mortality. *Neuroepidemiology* 2008, 30(2):93–100.
53. Kim BJ, Lee SH, Jung KH, Yu KH, Lee BC, Roh JK: Dynamics of obesity paradox after stroke, related to time from onset, age, and causes of death. *Neurology* 2012, 79(9):856–863.
54. Ovbiagele B, Bath PM, Cotton D, Vinisko R, Diener HC: Obesity and recurrent vascular risk after a recent ischemic stroke. *Stroke; a journal of cerebral circulation* 2011, 42(12):3397–3402.
55. Mak KH, Bhatt DL, Shao M, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Montalescot G, Steg PG, Steinhubl SR et al: The influence of body mass index on mortality and bleeding among patients with or at high-risk of atherothrombotic disease. *European heart journal* 2009, 30(7):857–865.
56. Curioni C, Andre C, Veras R: Weight reduction for primary prevention of stroke in adults with overweight or obesity. *The Cochrane database of systematic reviews* 2006(4):CD006062.
57. Sarikaya H: Hirnschlag und das Adipositas-Paradoxon. *Praxis*:in press.